Leitender Arzt
Klinik für Urologie
Funktion
Qualifikationen
Facharzt für Urologie
Speziell operative Urologie
Sprachen
Berufserfahrung
Seit 06/2022
Leitender Arzt
Klinik für Urologie
Kantonsspital Winterthur
(Prof. Dr. med. H. John)
08/2021 – 05/2022
Oberarzt
Klinik für Urologie
Universitätsspital Zürich
(Prof. Dr. Dr. med. D. Eberli)
01/2019 – 07/2021
Oberarzt
Klinik für Urologie
Kantonsspital Winterthur
(Prof. Dr. med. H. John)
07/2016 – 12/2018
Clinical & Research Fellow
Urologic Oncology
Universitätsklinik für Urologie
Medizinische Universität Wien
(Univ.Prof. Dr. med. S. Shariat)
01/2016 – 06/2016
Oberarzt
Klinik für Urologie
Kantonsspital Winterthur
(Prof. Dr. med. H. John)
04/2013 – 07/2013
Assistenzarzt
Neuro-Urologie
Schweizer Paraplegiker-Zentrum Nottwil
(Prof. Dr. med. J. Pannek)
07/2012 – 12/2015
Assistenzarzt
Klinik für Urologie
Kantonsspital Winterthur
(Prof. Dr. med. H. John)
07/2010 – 06/2012
Assistenzarzt
Chirugische Klinik
Spital Limmttal
(Prof. Dr. med. O. Schöb, Prof. Dr. med. U. Zingg)
09/2009 – 06/2010
Doktorand Harnblasenfunktionsstörungen
Anatomisches Institut
Universität Zürich
09/2009 – 06/2010
Assistenzarzt
Klinik für Urologie
Kantonsspital Winterthur
(Prof. Dr. med. H. John)
Lehraufträge
Seit 2024
Privatdozent
Medizinische Fakultät
Universität Zürich
Seit 2019
Klinische Kurse für Medizinstudenten
Medizinische Fakultät
Universität Zürich
2019 – 2021
Clinical Research Seminar II
Medical School, ETH Zürich
Ausbildung, Weiterbildung und akademische Laufbahn
03/2024
Schwerpunkt operative Urologie
03/2024
Habilitation und Venia Legendi
Medizinische Fakultät
Universität Zürich
05/2019
German Curriculum Robotic Urology
06/2017
Fellow of the European Board of Urology (FEBU)
03/2017
Facharzt für Urologie (FMH Urologie)
07/2011
Promotion zum Doktor der Medizin
Medizinische Fakultät
Universität Zürich
10/2008
Staatsexamen
Medizinische Fakultät
Universität Zürich
The Association of Ischemia Type and Duration with Acute Kidney Injury after Robot-Assisted Partial Nephrectomy.
Obrecht F, Padevit C, Froelicher G, Rauch S, Randazzo M, Shariat SF, John H, Foerster B.
(2023). Curr Oncol. doi: 10.3390/curroncol30110698.
Extraperitoneal extravesical robot-assisted simple prostatectomy (EE-RASP) with intraprostatic urethral reconstruction.
John, H., Burkhardt, O., Tutal, M., Padevit, C., & Foerster, B.
(2023). Urology Video Journal, 18, doi: 100207/j.urolvj.2023.100207
Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study.
Marcq, G., Foerster, B., Abufaraj, M., Matin, S. F., Azizi, M., Gupta, M., . . . Kassouf, W.
(2021). Eur Urol Focus. doi:10.1016/j.euf.2021.03.018
Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study.
Foerster, B., Abufaraj, M., Matin, S. F., Azizi, M., Gupta, M., Li, W. M., . . . Shariat, S. F.
(2021). Eur Urol. doi:10.1016/j.eururo.2021.05.004
Functional Outcomes after Local Salvage Therapies for Radiation-Recurrent Prostate Cancer Patients: A Systematic Review.
Abufaraj, M., Siyam, A., Ali, M. R., Suarez-Ibarrola, R., Yang, L., Foerster, B., & Shariat, S. F.
(2021). Cancers (Basel), 13(2). doi:10.3390/cancers13020244
Diagnostic Value of (18)F-fluorodeoxyglucose Positron Emission Tomography with Computed Tomography for Lymph Node Staging in Patients with Upper Tract Urothelial Carcinoma.
Voskuilen, C. S., Schweitzer, D., Jensen, J. B., Nielsen, A. M., Joniau, S., Muilwijk, T., . . .Hendricksen, K. (2020). Eur Urol Oncol, 3(1), 73-79. doi:10.1016/j.euo.2019.09.004
Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study.
Soria, F., Moschini, M., D’Andrea, D., Abufaraj, M., Foerster, B., Mathiéu, R., . . . Shariat, S. F.
(2020). Eur Urol Focus, 6(6), 1233-1239. doi:10.1016/j.euf.2018.11.002
Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma.
Pradere, B., D’Andrea, D., Schuettfort, V. M., Foerster, B., Quhal, F., Mori, K., . . . S, F. S.
(2020). World J Urol. doi:10.1007/s00345-020-03479-3
Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer. Kimura, S., D’Andrea, D., Iwata, T., Foerster, B., Janisch, F., Parizi, M. K., . . . Shariat, S. F.
(2020). World J Urol, 38(10), 2501-2511. doi:10.1007/s00345-019-03038-5
Performance of [(68)Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis.
Kimura, S., Abufaraj, M., Janisch, F., Iwata, T., Parizi, M. K., Foerster, B., . . . Shariat, S. F.
(2020). Prostate Cancer Prostatic Dis, 23(1), 1-10. doi:10.1038/s41391-019-0156-z
Efficacy of Preoperative Chemotherapy for High Risk Upper Tract Urothelial Carcinoma.
Foerster, B., Abufaraj, M., Petros, F., Azizi, M., Gupta, M., Schweitzer, D., . . . Shariat, S. F.
(2020). J Urol, 203(6), 1101-1108. doi:10.1097/ju.0000000000000737
The Performance of Tumor Size as Risk Stratification Parameter in Upper Tract Urothelial Carcinoma (UTUC).
Foerster, B., Abufaraj, M., Mari, A., Seisen, T., Bandini, M., Schweitzer, D., . . . Shariat, S. F.
(2020). Clin Genitourin Cancer. doi:10.1016/j.clgc.2020.09.002
Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy.
Zamboni, S., Foerster, B., Abufaraj, M., Seisen, T., Roupret, M., Colin, P., . . . Moschini, M.
(2019). BJU Int, 124(5), 738-745. doi:10.1111/bju.14751
Role of serum cholinesterase in patients treated with salvage radical prostatectomy.
Vartolomei, M. D., D’Andrea, D., Chade, D. C., Soria, F., Kimura, S., Foerster, B., . . . Shariat, S.F. (2019). Urol Oncol, 37(2), 123-129. doi:10.1016/j.urolonc.2018.11.013
Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma.
Rieken, M., Boorjian, S. A., Kluth, L. A., Capitanio, U., Briganti, A., Thompson, R. H., . . .Shariat, S. F. (2019). World J Urol, 37(8), 1631-1637. doi:10.1007/s00345-018-2555-5
External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.
Moschini, M., Zaffuto, E., Karakiewicz, P. I., Andrea, D. D., Foerster, B., Abufaraj, M., . . . Shariat, S. F. (2019). Eur Urol, 75(2), 319-328. doi:10.1016/j.eururo.2018.09.034
A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens.
Mari, A., Kimura, S., Foerster, B., Abufaraj, M., D’Andrea, D., Hassler, M., . . . Shariat, S. F.
(2019). BJU Int, 123(1), 11-21. doi:10.1111/bju.14417
Prognostic Value of Concomitant Carcinoma In Situ in the Radical Cystectomy Specimen: A Systematic Review and Meta-Analysis.
Kimura, S., Mari, A., Foerster, B., Abufaraj, M., Vartolomei, M. D., Stangl-Kremser, J., . . . Shariat, S. F. (2019). J Urol, 201(1), 46-53. doi:10.1016/j.juro.2018.05.162
Comparison of perioperative complications and health-related quality of life between robot-assisted and open radical cystectomy: A systematic review and meta-analysis.
Kimura, S., Iwata, T., Foerster, B., Fossati, N., Briganti, A., Nasu, Y., . . . Shariat, S. F.
(2019). Int J Urol, 26(8), 760-774. doi:10.1111/iju.14005
Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer. Kimura, S., D, D. A., Soria, F., Foerster, B., Abufaraj, M., Vartolomei, M. D., . . . Shariat, S. F.
(2019). Urol Oncol, 37(3), 179.e119-179.e128. doi:10.1016/j.urolonc.2018.11.005
Oncologic outcomes after robot-assisted versus open radical cystectomy: a systematic review and meta-analysis.
Iwata, T., Kimura, S., Foerster, B., Fossati, N., Briganti, A., Karakiewicz, P. I., . . . Shariat, S. F.
(2019). World J Urol, 37(8), 1557-1570. doi:10.1007/s00345-019-02708-8
Perioperative blood transfusion affects oncologic outcomes after nephrectomy for renal cell carcinoma: A systematic review and meta-analysis.
Iwata, T., Kimura, S., Foerster, B., Abufaraj, M., Karakiewicz, P. I., Preisser, F., . . . Shariat, S. F.
(2019). Urol Oncol, 37(4), 273-281. doi:10.1016/j.urolonc.2019.01.018
Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature.
Foerster, B., D’Andrea, D., Abufaraj, M., Broenimann, S., Karakiewicz, P. I., Rouprêt, M., . . . Soria, F. (2019). Urol Oncol, 37(7), 430-436. doi:10.1016/j.urolonc.2019.02.004
Caveolin-1 Expression in Upper Tract Urothelial Carcinoma.
D’Andrea, D., Moschini, M., Foerster, B., Abufaraj, M., Margulis, V., Karam, J., . . . Shariat, S.F.
(2019). Eur Urol Focus, 5(1), 97-103. doi:10.1016/j.euf.2017.06.011
Optimal Management of Upper Tract Urothelial Carcinoma: an Unmet Need.
Azizi, M., Cheriyan, S. K., Peyton, C. C., Foerster, B., Shariat, S. F., & Spiess, P. E.
(2019). Curr Treat Options Oncol, 20(5), 40. doi:10.1007/s11864-019-0637-2
Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes.
Abufaraj, M., Foerster, B., Schernhammer, E., Moschini, M., Kimura, S., . . . Shariat, S. F.
(2019). Eur Urol, 75(4), 649-658. doi:10.1016/j.eururo.2018.11.052
Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis.
Vartolomei, M. D., Porav-Hodade, D., Ferro, M., Mathieu, R., Abufaraj, M., Foerster, B., . . .
Shariat, S. F.
(2018). Urol Oncol, 36(9), 389-399. doi:10.1016/j.urolonc.2018.05.014
Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients.
Vartolomei, M. D., Kimura, S., Ferro, M., Vartolomei, L., Foerster, B., Abufaraj, M., & Shariat, S. F.
(2018). World J Urol, 36(7), 1019-1029. doi: 0.1007/s00345-018-2235-5
The impact of moderate wine consumption on the risk of developing prostate cancer.
Vartolomei, M. D., Kimura, S., Ferro, M., Foerster, B., Abufaraj, M., Briganti, A., . . . Shariat, S.F. (2018). Clin Epidemiol, 10, 431-444. doi:10.2147/clep.s163668
Oncologic outcomes after minimally invasive surgery for cT1 renal masses: a comprehensive review.
Vartolomei, M. D., Foerster, B., Kimura, S., Autorino, R., Shariat, S. F., & Seitz, C.
(2018). Curr Opin Urol, 28(2), 132-138. doi:10.1097/mou.0000000000000477
Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer.
Rieken, M., Shariat, S. F., Kluth, L., Crivelli, J. J., Abufaraj, M., Foerster, B., . . . Xylinas, E.
(2018). Urol Oncol, 36(1), 8.e17-18.e24. doi:10.1016/j.urolonc.2017.08.027
Predictors of Cancer-specific Survival After Disease Recurrence in Patients With Renal Cell Carcinoma: The Effect of Time to Recurrence.
Rieken, M., Kluth, L. A., Fajkovic, H., Capitanio, U., Briganti, A., Krabbe, L. M., . . . Shariat, S. F.
(2018). Clin Genitourin Cancer, 16(4), e903-e908. doi:10.1016/j.clgc.2018.03.003
Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.
Özsoy, M., D’Andrea, D., Moschini, M., Foerster, B., Abufaraj, M., Mathieu, R., . . . Shariat, S.F.
(2018). Urol Oncol, 36(4), 158.e151-158.e156. doi:10.1016/j.urolonc.2017.12.003
A systematic review and meta-analysis of lymphovascular invasion in patients treated with radical cystectomy for bladder cancer.
Mari, A., Kimura, S., Foerster, B., Abufaraj, M., D’Andrea, D., Gust, K. M., & Shariat, S. F.
(2018). Urol Oncol, 36(6), 293-305. doi:10.1016/j.urolonc.2018.03.018
Oncologic Effect of Cumulative Smoking Exposure in Patients Treated With Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer.
Mari, A., Abufaraj, M., Foerster, B., Özsoy, M., Briganti, A., Rouprêt, M., . . . Shariat, S. F.
(2018). Clin Genitourin Cancer, 16(3), e619-e627. doi:10.1016/j.clgc.2017.10.015
Prognostic Value of Serum Cholinesterase in Non-muscle-invasive Bladder Cancer.
Kimura, S., Soria, F., D’Andrea, D., Foerster, B., Abufaraj, M., Vartolomei, M. D., . . . Gust, K. M. (2018). Clin Genitourin Cancer, 16(6), e1123-e1132. doi:10.1016/j.clgc.2018.07.002
Association of Smoking Status With Recurrence, Metastasis, and Mortality Among Patients With Localized Prostate Cancer Undergoing Prostatectomy or Radiotherapy: A Systematic Review and Meta-analysis.
Foerster, B., Pozo, C., Abufaraj, M., Mari, A., Kimura, S., D’Andrea, D., . . . Shariat, S. F.
(2018). JAMA Oncol, 4(7), 953-961. doi:10.1001/jamaoncol.2018.1071
Robot-assisted partial nephrectomy: systematic review of functional results.
Foerster, B., Kimura, S., Vartolomei, M. D., Abufaraj, M., Gust, K., Fajkovic, H., . . . Seitz, C.
(2018). Curr Opin Urol, 28(2), 123-131. doi:10.1097/mou.0000000000000482
Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: A clinical decision-making tool.
D’Andrea, D., Abufaraj, M., Susani, M., Ristl, R., Foerster, B., Kimura, S., . . . Shariat, S. F.
(2018). Urol Oncol, 36(5), 239.e231-239.e237. doi:10.1016/j.urolonc.2018.01.018
Clinical value of cholinesterase in the prediction of biochemical recurrence after radical prostatectomy.
D’Andrea, D., Soria, F., Abufaraj, M., Gust, K., Foerster, B., Vartolomei, M. D., . . . Shariat, S. F.
(2018). Urol Oncol, 36(12), 528.e527-528.e513. doi:10.1016/j.urolonc.2018.09.015
Progressive tissue biomarker profiling in non-muscle-invasive bladder cancer.
D’Andrea, D., Hassler, M. R., Abufaraj, M., Soria, F., Ertl, I. E., Ilijazi, D., . . . Shariat, S. F
(2018). Expert Rev Anticancer Ther, 18(7), 695-703. doi:10.1080/14737140.2018.1474104
Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. Cumberbatch, M. G. K., Foerster, B., Catto, J. W. F., Kamat, A. M., Kassouf, W., . . . Gontero, P.
(2018). Eur Urol, 73(6), 925-933. doi:10.1016/j.eururo.2018.02.014
Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder.
Abufaraj, M., Shariat, S. F., Foerster, B., Pozo, C., Moschini, M., D’Andrea, D., . . . Seebacher, V. (2018). World J Urol, 36(2), 231-240. doi:10.1007/s00345-017-2116-3
Preoperative anemia is associated with disease recurrence and progression in patients with non-muscle-invasive bladder cancer.
Soria, F., Moschini, M., Abufaraj, M., Wirth, G. J., Foerster, B., Gust, K. M., . . . Shariat, S. F.
(2017). Urol Oncol, 35(3), 113.e119-113.e114. doi:10.1016/j.urolonc.2016.10.021
Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer.
Soria, F., Lucca, I., Moschini, M., Mathieu, R., Rouprêt, M., Karakiewicz, P. I., . . . Shariat, S. F.
(2017). Urol Oncol, 35(6), 356-362. doi:10.1016/j.urolonc.2017.02.009
Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy.
Rieken, M., Shariat, S. F., Karam, J. A., Foerster, B., Khani, F., Gust, K., . . . Margulis, V.
(2017). J Urol, 198(6), 1269-1277. doi:10.1016/j.juro.2017.06.096
External Validation of the Pathologic Nodal Staging Score for Prostate Cancer: A Populationbased Study.
Rieken, M., Kluth, L. A., Seitz, C., Abufaraj, M., Foerster, B., Mathieu, R., . . . Seebacher, V.
(2017). Clin Genitourin Cancer. doi:10.1016/j.clgc.2017.08.002
Impact of Intra- and Postoperative Blood Transfusion on the Incidence, Timing, and Pattern of Disease Recurrence After Radical Cystectomy.
Moschini, M., Soria, F., Abufaraj, M., Foerster, B., D’Andrea, D., Damiano, R., . . . Shariat, S. F.
(2017). Clin Genitourin Cancer, 15(4), e681-e688. doi:10.1016/j.clgc.2017.01.001
Pure but Not Mixed Histologic Variants Are Associated With Poor Survival at Radical Cystectomy in Bladder Cancer Patients.
Moschini, M., Shariat, S. F., Lucianò, R., D’Andrea, D., Foerster, B., Abufaraj, M., . . . Gallina, A.
(2017). Clin Genitourin Cancer, 15(4), e603-e607. doi:10.1016/j.clgc.2016.12.006
Is transurethral resection alone enough for the diagnosis of histological variants? A singlecenter study.
Moschini, M., Shariat, S. F., Freschi, M., Soria, F., D’Andrea, D., Abufaraj, M., . . . Colombo, R.
(2017). Urol Oncol, 35(8), 528.e521-528.e525. doi:10.1016/j.urolonc.2017.03.024
Predicting local failure after radical cystectomy in patients with bladder cancer: Implications for the selection of candidates at adjuvant radiation therapy.
Moschini, M., Shariat, S. F., Abufaraj, M., Foerster, B., D, D. A., Soria, F., . . . Gallina, A.
(2017). Urol Oncol, 35(12), 672.e671-672.e676. doi:10.1016/j.urolonc.2017.08.013
Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy.
Moschini, M., Foerster, B., Abufaraj, M., Soria, F., Seisen, T., Roupret, M., . . . Shariat, S. F.
(2017). World J Urol, 35(10), 1541-1547. doi:10.1007/s00345-017-2026-4
Genetic determinants for chemo- and radiotherapy resistance in bladder cancer.
Mari, A., D’Andrea, D., Abufaraj, M., Foerster, B., Kimura, S., & Shariat, S. F.
(2017). Transl Androl Urol, 6(6), 1081-1089. doi:10.21037/tau.2017.08.19
Frequency and prognostic significance of incidental prostate cancer at radical cystectomy: Results from an international retrospective study.
Malte, R., Kluth, L. A., Kaushik, D., Boorjian, S. A., Abufaraj, M., Foerster, B., . . . Seebacher, V.
(2017). Eur J Surg Oncol, 43(11), 2193-2199. doi:10.1016/j.ejso.2017.08.013
Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma.
Foerster, B., Moschini, M., Abufaraj, M., Soria, F., Gust, K. M., Rouprêt, M., . . . Shariat, S. F.
(2017). Clin Genitourin Cancer, 15(6), e1039-e1045. doi:10.1016/j.clgc.2017.06.003
Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancer. Abufaraj, M., Shariat, S. F., Haitel, A., Moschini, M., Foerster, B., Chłosta, P., . . . Albrecht, W.
(2017). Urol Oncol, 35(5), 264-271. doi:10.1016/j.urolonc.2017.01.012
Prognostic Role of N-cadherin Expression in Patients With Invasive Bladder Cancer.
Abufaraj, M., Haitel, A., Moschini, M., Gust, K., Foerster, B., Özsoy, M., . . . Shariat, S. F.
(2017). Clin Genitourin Cancer. doi:10.1016/j.clgc.2017.07.001
Preoperative anemia is associated with disease recurrence and progression in patients with non-muscle-invasive bladder cancer.
Soria, F., Moschini, M., Abufaraj, M., Wirth, G. J., Foerster, B., Gust, K. M., . . . Shariat, S. F.
(2016). Urol Oncol. doi:10.1016/j.urolonc.2016.10.021
Das Prostatakarzinom: aktuelle Diagnostik und Therapiestandard.
Brachlow, J., Kalin, M., Randazzo, M., Forster, B., & John, H.
(2016). Praxis (Bern 1994), 105(16), 971-977. doi:10.1024/1661 8157/a002437
Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery.
Abufaraj, M., Gust, K., Moschini, M., Foerster, B., Soria, F., Mathieu, R., & Shariat, S. F.
(2016). Transl Androl Urol, 5(5), 735-744. doi:10.21037/tau.2016.08.23
Establishment of a protocol for large-scale gene expression analyses of laser capture microdissected bladder tissue.
Horstmann, M., Foerster, B., Brader, N., John, H., & Maake, C.
(2012). World J Urol, 30(6), 853-859. doi:10.1007/s00345-012-0881-6